Biotech | December 05, 2021
SPARC to licence Biomodifying’s IP
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
Venus Remedies has reported consolidated financial results for the period ended September 30, 2021
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
The board has approved the settlement of US $ 248 million towards Direct Purchaser group and Retailer Opt-Out group subject to court approval
Over 70 per cent of the world’s population have no access to MRI scanners and the situation is not that encouraging in India where there are only 0.4 MRI scanners per thousand people
TCS provides clinical research services such as clinical data management, regulatory affairs, pharmacovigilance, risk-based monitoring, biostatistics and programming, medical writing, medical affairs and medico marketing, and health economics and outcomes research
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
Tiger can no longer make an important biotin intermediate using a DSM patented process.
Subscribe To Our Newsletter & Stay Updated
